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Background: Atherosclerosis is a major cause of cardiac events and mortality in patients suffering from chronic
kidney disease (CKD). Moreover, the risk of cardiovascular disease (CVD) development in patients with CKD increases
as kidney function declines. Although the close connection between atherosclerosis and kidney dysfunction is
undeniable, particular risk factors and specific mechanisms that promote CVD in patients with CKD remain unclear.
To gain insight into better recognition of the mechanisms of accelerated atherosclerosis in patients with CKD, we
performed a comparative proteomic analysis of blood plasma from patients in various stages of CKD and thus
distinct progression of atherosclerosis (n = 90), patients with advanced CVD and normal renal function (n = 30) and
healthy volunteers (n = 30).
Methods: Plasma samples were depleted using affinity chromatography and divided into three fractions: high-
abundant, low-abundant and low-molecular weight proteins. The first two fractions were analyzed by two-
dimensional gel electrophoresis and mass spectrometry, the last one has been subjected to direct MS/MS analysis.
A proteomic profiles for high-abundant, low-abundant and low-molecular weight proteins fractions were obtained.
Differential accumulated proteins were confirmed by selected reaction monitoring analysis (SRM). The Gene
Ontology (GO) function and the interaction networks of differentially expressed proteins were then analyzed.
Results: Forty-nine proteins (13 high- and 36 low-molecular mass) showed differences in accumulation levels. For
eleven of them differential expression were confirmed by selected reaction monitoring analysis. Bioinformatic
analysis showed that identified differential proteins were related to three different processes: the blood coagulation
cascade, the transport, binding and metabolism of lipoproteins and inflammatory processes.
Conclusions: Obtained data provide an additional line of evidence that different molecular mechanisms are
involved in the development of CKD- and CVD-related atherosclerosis. The abundance of some anti-atherogenic
factors revealed in patients with CKD suggests that these factors are not associated with the reduction of
atherosclerosis progression in CKD that is typically observed in “classical” CVD. Moreover, obtained data also suggest
that mechanism of CVD acceleration may be different in initial and advanced stages of CKD. Undoubtedly, in
advanced stages of CKD inflammation is highly pronounced.
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Chronic kidney disease (CKD) is defined as impaired
kidney function that is characterized by a progressive de-
crease in the glomerular filtration rate (GFR) or an in-
crease in proteinuria over a period of at least 3 months
[1]. Guidelines from the Kidney Disease Outcomes
Quality Initiative (K/DOQI) [2] place patients with CKD
into one of five stages, based on their estimated GFRs
(eGFRs). The 1st stage of CKD (CKD1) is the mildest
one, and although eGFRs are similar to those observed
in healthy people (eGFR above 90 mL/min/1.73 m2),
urine findings or structural abnormalities suggest CKD.
In the 2nd stage of CKD (CKD2), a mild reduction in the
GFR (eGFR between 89 and 60 mL/min/1.73 m2) is ob-
served. In the 3rd and 4th stages of CKD, moderate and
severe kidney damage occur (CKD3: GFR 30–59 mL/
min/1.73 m2; CKD4: 15–29 mL/min/1.73 m2). The 5th
stage of CKD (CKD5) is the most advanced stage and is
indicative of kidney failure (GFR <15 mL/min/1.73 m2).
Atherosclerosis is one of the most serious and fre-
quent complications that occurs in patients suffering
from CKD and is a major cause of mortality in this
group of patients [3]. The risk of developing cardiovas-
cular disease (CVD) can be predicted from the GFR, and
increases as the GFR declines [4,5]. Additionally, CKD
patients with GFR ≤60 mL/min/1.73 m2 are considered
to have an elevated risk of cardiovascular events among
them heart failure, ischemic heart disease, myocardial in-
farction and stroke [6]. Many studies in various popula-
tions have reported that a decreased GFR and increased
albuminuria are associated with CVD in graded associ-
ation. Cardiovascular mortality is approximately two
times higher in patients with stage 3 CKD and three
times higher in patients with stage 4 CKD than in indi-
viduals with normal kidney function [3]. Therefore, al-
though the close connection between kidney dysfunction
and atherosclerosis is indisputable, the frequency and se-
verity of cardiovascular complications is disproportion-
ate to the underlying risk factor profile.
In recent years, considerable research efforts have
been directed toward identifying the mechanism of ac-
celerated development of CVD in patients with CKD.
Traditional risk factors that support the development of
classical CVD (i.e., hypertension, hypercholesterolemia,
obesity and hyperhomocysteinemia) alone cannot ex-
plain the high incidence of CVD in patients with CKD.
Several other risk factors may be more important, in-
cluding inflammation, endothelial dysfunction, oxidative
stress, vascular calcification and volume overload. The
close relationship between CVD and CKD is most likely
due to the co-existence of both traditional and novel
(non-traditional) cardiovascular risk factors. The com-
bination of these factors may lead to surprising results.
For example, the concentration of serum cholesterol hasa widely recognized impact on atherogenesis in the gen-
eral population. Paradoxically, the significance of this
factor in the pathogenesis of CKD-related atherosclerosis
(CKDA) is not so obvious, particularly in the advanced
stages of CKD, wherein high serum cholesterol levels
seem to protect against cardiovascular death. This obser-
vation, together with other similar findings, has led to
the term ‘reverse epidemiology’ [7,8].
Thus, the exact participation and association of par-
ticular risk factors and specific mechanisms that pro-
mote CVD in patients with CKD remain unclear. To
better understand these mechanisms, we have attempted
to determine the changes induced in the proteome of
blood plasma from patients with different stages of CKD
and CVD. In our earlier studies we performed 2DE/MS
analysis of raw plasma samples without depletion of high
abundant proteins [9]. In the present work, we sought to
expand the catalog of differentially expressed plasma
proteins related to CKD and CKDA. Thus, we analyzed
three different fractions of plasma proteins: high-
abundance proteins (HAPs), low-abundance proteins
(LAPs) and low-molecular-weight proteins (LMWPs, that
is, below 5 kDa) in patients with diagnosed CKD and
CVD as well as in healthy volunteers (HVs). All of the
studied CKD patients revealed presence of atherosclerosis
on different progression stage. All CVD patients showed
advanced cardiovascular disease symptoms and had none
clinical symptoms of renal dysfunction. All plasma protein




The study protocol conforms to the ethical guidelines of
the World Medical Association Declaration of Helsinki.
Before the project commenced, appropriate approval
was obtained from the Bioethical Commission of the
Karol Marcinkowski University of Medical Sciences (no.
14/07 04.01.2007). All participating individuals provided
signed informed consent for treatment and study. Char-
acteristics of the studied population are shown in Table 1.
Study involved 150 persons divided into five equal
groups. The patients were matched for age and gender.
The majority of them were patients with CKD (90 per-
sons) who were treated in the Department of Nephrol-
ogy, Transplantology and Internal Medicine at Poznan
University of Medical Sciences. Based on the National
Kidney Foundation Kidney Disease Outcomes Quality
Initiative guidelines [2], the examined CKD patients
were divided into three groups according to their eGFR,
which was calculated by the formula developed by Levey
et al. [10]. The first group, CKD1-2, contained patients
in the initial stages of CKD (the 1st and 2nd stages of
CKD, with eGFR = 90–60 mL/min/1.73 m2). The second
Table 1 Demographic data and clinical characteristics of the study population (n = 150)
CKD1-2 CKD 3-4 CKD5 CVD HV p
Age [years] 61.5 +/− 9.15 59.5+/− 6.3 60.1+/−10.1 61 +/− 7.07 60.5 +/− 10.1 NS
Males/females 17/13 17/13 17/13 17/13 17/13 NS
eGFR [ml/min/1.73 m2] 77.04 +/− 22.9 19.1 +/− 8.0 5.75 +/− 7.1 92.7 +/− 21.1 123.6 +/− 17.6 0.000
BMI [kg/m2] 27.11+/− 4.21 28.31+/− 1.21 25.74 +/− 3.42 28.98 +/− 3.21 24.98 +/− 2.87 0.000
Arterial hypertension 100% 100% 100% 100% 0% 0.000
History of myocardial infarction/stroke 15% 21% 59% 68% 0% 0.000
Systolic BP [mmHg] 124.76 +/− 13.21 138.21+/−7.26 134.42 +/− 26.78 115.28 +/− 12.23 124.32 +/− 12.31 0.002
Diastolic BP [mmHg] 76.27 +/− 11.12 89.12 +/− 74.23 77.13 +/− 19.21 71.21 +/− 11.23 68.34 +/− 14.21 0.021
Statin treatment 61% 49% 68% 92% 0% 0.000
IACE treatment 84% 48% 60% 76% 0% 0.000
Total cholesterol [mg/dL] 229.06 +/− 51.12 184.33 +/− 28.61 179.53 +/− 38.39 193.22 +/− 38.14 185.11 +/− 29.12 0.031
HDL cholesterol [mg/dL] 55.1 +/− 10.15 58.4 +/− 7.64 45.18 +/− 23.076 46.58 +/− 15.12 70.11 +/− 5.14 0.000
LDL cholesterol [mg/dL] 169.66 +/− 41.25 120.06 +/− 17.11 103.24 +/− 40.05 114.65 +/− 34.16 91.92 +/− 29.14 0.000
Triglycerides [mg/dL] 170.41 +/− 68.16 117.24 +/− 21.18 133.35 +/− 50.83 139.68 +/− 60.51 121.2 +/− 34.01 0.042
hsCRP [mg/L] 1.62 +/− 0.36 9.19 +/− 2.15 12.32 +/− 18.05 5.88 +/− 1.14 1.09 +/− 0.15 0.001
CIMT [mm] 0.71 +/− 0.21 0.83 +/− 024 0.92 +/− 0.42 0.72 +/− 0.32 0.45 +/− 0.28 0.000
Diagnosis of CKD [number of patients]
Hypertensive nephropathy 10 11 12
Chronic glomerulonephritis 7 7 7
Chronic interstitial nephritis 9 6 6
Polycystic kidney disease 0 1 2
Others or unknown 4 5 3
No. (%) or mean value ± SD. p < 0.05 was considered as statistically significant, NS - indicates not significant differences between all the studied groups. eGFR -
estimated glomerular filtration rate, BMI - body mass index, BP - blood pressure, IACE - angiotensin-converting enzyme inhibitors, HDL cholesterol - high density
lipoprotein cholesterol, LDL cholesterol - low density lipoprotein cholesterol, hsCRP - high-sensitivity C-reactive protein , CIMT - carotid intima media thickness.
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and 4th stages of CKD, with eGFR = 59–15 mL/min/
1.73 m2. The third group, CKD5, comprised patients
with eGFR <15 mL/min/1.73 m2 who were hemodia-
lyzed for 39.6 ± 9.5 months (mean ± SD) with prescrip-
tions of 4.5-5.5 h/session, three times per week. CKD
patients varied in progression of atherosclerosis and per-
centage of cardiovascular events. CKD1-2 showed the
first symptoms of hypertension or ischemic heart dis-
ease. In more advanced stages of CKD mild and severe
cardiovascular disease symptoms were observed. Fifty-
nine percent of CKD5 patients have a history of myocar-
dial infarction or stroke (Table 1).
A fourth group (called CVD) included 30 patients with
a history and symptoms of the atherosclerotic occlusive
disease, admitted for angiography to the Department of
Internal Medicine, Division of Cardiac Intensive Care in
Poznan University of Medical Sciences. All CVD pa-
tients have at least one artery stenosis causing lumen re-
duction of at least 50%. Sixty-eight percent of CVD
patients revealed history of myocardial infarction or
stroke. No subjects from the CVD group had any clinical
symptoms of renal dysfunction.A fifth control group (HV) contained 30 healthy vol-
unteers. Persons with diabetes mellitus, acute inflamma-
tory processes and malignant tumors either presently or
within the past 10 years were excluded from the study.
All of the studied subjects were diagnosed with athero-
sclerosis on the basis of their medical history (history of
myocardial infarction or/and ischemic stroke), their
lipids metabolism parameters, systolic and diastolic
blood pressure values and carotid intima media thick-
ness (CIMT). For all CKD and CVD patients, blood
samples were collected at the same time that standard
monitoring blood tests were performed. In the case of
hemodialyzed patients, blood samples were always
drawn before the second hemodialysis session of the
week. Peripheral blood was collected into a closed
monovette system containing EDTA and was centrifuged
immediately at 1,000 g for 15 min. The obtained super-
natants were then centrifuged at 16,000 g for 15 min at
4°C and frozen at −80°C.
Isolation of LAPs, HAPs and LMWPs from plasma samples
Immunoaffinity depletion was used to isolate LAPs,
HAPs and LMWPs. Individual plasma samples were
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highly abundant proteins with a MARS-Hu7 affinity col-
umn (Agilent Technologies, USA). The MARS-Hu7 spin
column removed the 7 most abundant plasma proteins
(human albumin, IgG, α1-antitrypsin, IgA, transferrin,
HP and fibrinogen), which constitute approximately 90%
of the plasma proteome. Human plasma (20 μL) from
the patient and HV group was diluted to 400 μL with
“Buffer A” (Agilent Technologies), centrifuged for 1 min
through a 0.22 μm spin filter tube (Agilent Technolo-
gies, USA) at 14,000 g and then prepared according to
the manufacturer’s instructions in two cycles. Aliquots
of the flow-through fractions containing LAPs as well as
the bound fractions with HAPs were desalted by buffer
exchange run three times using centrifugal filter devices
with a 5-kDa cutoff (Amicon Ultra, Millipore). The flow-
through after filtration of the LAP fraction with 5-kDa
filters was evaporated on a SpeedVac and then directly
analyzed by MALDI-TOF/TOF as LMWPs. Samples
were stored at −80°C prior to analysis, and the protein
concentration was measured using a commercial 2-D
Quant kit (GE Healthcare).
2-D electrophoresis
A total of 100 μg of the LAP fractions deriving from in-
dividual samples was separated using 7-cm IPG strips
(pH 4–7, GE Healthcare) in four repetitions. 650 μg of
the HAP fractions was separated using 24-cm IPG strips
(pH 4–7) in at least three repetitions. Strips were ac-
tively rehydrated overnight in IEF buffer containing
plasma proteins. The strips were subjected to IEF on
IPGphor III (GE Healthcare) using a ramping voltage of
50–8,000 V to a final voltage of 75,000 Vh for 24-cm
IPG strips and 50–5,000 V to 18,000 Vh for 7-cm strips.
Reduction, alkylation and separation in the second di-
mension were performed as previously described [9,11].
After electrophoresis, gels were stained with Blue Silver
overnight [12] and scanned using the LabScan program
with a Umax scanner (GE Healthcare).
The images were analyzed using the Image Master
Platinum software, version 6.0 (GE Healthcare). In total
approximately 1,000 obtained images were analyzed.
Spots were detected automatically without filtering. Gel
patterns were automatically matched together between
classes. In addition, all individually matched spots were
validated manually to ensure that spot matching was
correct. The relative abundance of each spot (%vol) was
calculated as its volume divided by the total volume of
matched spots. 2DE reproducibility was assessed by scat-
ter plotting and correlation coefficient determination
based on %vol parameter. Images showing the correl-
ation coefficient below 0.7 were rejected from analysis.
The final datasets consisted of 443 and 332 images for
LAP and HAP fraction, respectively. Average relativeabundance of protein spot for each group was calculated
for all obtained %vol (all samples in all repetitions in
group). To find differentially expressed proteins, gap and
ratio measures were taken into account. For differentiat-
ing proteins threshold 1.6 was selected but only with re-
strictive p value below 0.001. However only proteins that
were validated later with SRM analysis with a threshold
greater than 1.5 were accepted as differential accumulat-
ing proteins. Protein spots were manually excised from
gels, transferred to Eppendorf tubes and stored at −80°C
prior to MS analysis.
In-gel digestion
Individual protein spots were cut into small pieces, rinsed
twice in 100 μL of washing buffer (50 mM NH4HCO3/
100% ACN (vol. 1:1)) for 15 min and dehydrated in 100%
ACN. The dried gel spots were rehydrated by the addition
of 10 μL of digestion buffer (25 mM ammonium bicarbon-
ate and 0.2 μg of sequencing-grade trypsin (Promega)). Di-
gestion was performed overnight at 37°C. Peptides were
extracted with 10% ACN.
Mass spectrometry (MS)
Protein identification
Digested proteins were identified using a MALDI-TOF/
TOF mass spectrometer. The MALDI spectra were ac-
quired on an UltrafleXtreme (Bruker Daltonics, Germany)
mass spectrometer operated in reflector mode using de-
layed ion extraction. Positively charged ions in the m/z
range of 800–3500 were analyzed. For each sample, 0.5 μL
was co-crystallized with CHCA matrix and spotted directly
onto the MALDI AnchorChip target (Bruker Daltonics,
Germany). The MS spectra were externally calibrated
using the Peptide Calibration Standard mixture (Bruker
Daltonics, Germany). Flex control v. 3.3 was used for the
acquisition of spectra, and all further data processing was
performed using Flex analysis v. 3.3. The spectrometric
analysis was performed in an automatic dependent mode
under the control of BioTools 3.2 and WARP-LC 1.3 soft-
ware. Non-redundant precursor peptides were selected for
MS/MS with a signal-to-noise threshold of 12. A max-
imum of 20 precursor ions per spot were chosen for MS/
MS analysis. Monoisotopic peptide masses were assigned
and used for databases research. Protein database searches
using combined PMF and MS/MS datasets were per-
formed via BioTools 3.2 (Bruker Daltonics, Germany).
Proteins were identified using the Mascot (Matrix Science,
London, UK) program against the SwissProt (2014; 545 388
sequences in total) and NCBI (2011; 13 366 630 sequences
in total) databases. The false discovery rate (FDR) for pep-
tide identification was 0.05 in all analyses. The protein
search was performed using the following search parame-
ters: precursor-ion mass tolerance, +/−0.1 Da; fragment-ion
mass tolerance, +/−0.4 Da and cysteine-treated with
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dized methionine. Trypsin was set as the enzyme, with a
maximum of one missed cleavage. Proteins were identified
on the basis of at least two unique peptides with peptide
score higher than 40 (p < 0.05).
Analysis of LMWPs
Low-molecular proteins obtained from individual plasma
samples after centrifugal ultrafiltration with a 5-kDa fil-
ter were analyzed directly by MS without electrophoretic
separation. Samples that were not trypsin digested were
co-crystallized with sinapinic acid matrix, spotted on a
MALDI AnchorChip target and analyzed in the m/z
range 2,000-12,000 Da. All samples were analyzed in five
technical replications. For data validation, external calibra-
tion was performed with a standard mixture of proteins
(Bruker Daltonics, Germany). Visualization and analysis of
the obtained spectra as well as principal component ana-
lysis (PCA) were performed with ClinProTools 2.2 (Bruker
Daltonics). Differential components with fold change >2
and p values below 0.01 were considered as statistically sig-
nificant. Differential LMWPs were identified using TOF/
TOF fragmentation. MS/MS data were searched against
the Mascot with non-enzyme settings.
Validation of potential biomarkers by SRM
Proteins that were identified as differentially expressed
were validated by SRM analysis. Two reaction monitor-
ing transitions were determined empirically for all pro-
teins. They were calculated based on the analysis of
fragmentation spectra obtained after in-gel digestion of
proteins that were identified as differentially expressed.
The peptides and transitions selected for SRM analysis
are presented in Additional file 1. Transitions for each
peptide were analyzed in separate MS/MS experiments.
All peptide sequences were analyzed with NCBI BLAST
using non-redundant protein sequences database and
blastp algorithm to ensure that the sequences were
unique. Then, all transitions were tested using in-
solution digested plasma proteins. SRM analyses were
conducted on pulled of five plasma samples from each
group. The plasma samples deriving from five individ-
uals were diluted with Milli-Q water, aliquoted into
10 μg samples and pooled. The pooling strategy in each
experimental group was as follows: 1st SRM run consist
samples 1 to 5; 2nd run: 6 to 10; 3rd run: 11 to 15; 4th
run: 16 to 20, 5th run: 21 to 25 and 6th run: 26 to 30.
This scheme was repeated for each experimental group.
Four separate aliquots of pooled plasma samples were
processed as technical replicates. Therefore the final
datasets consisted of 120 SRM analyses. We did not
pulled all the samples in one set to minimize the loss of
information about the biological variation. Therefore,
this experimental design consists of a mix of biologicaland technical replicates. One microliter of prepared
sample was mixed with 50 mM ammonium bicarbonate
(pH 8.0) to a final volume of 60 μL. Then, the samples
were reduced in the presence of 50 mM NH4HCO3 with
5.6 mM DTT for 5 min at 95°C and alkylated with
5 mM iodoacetamide for 20 min in the dark at RT. The
proteins were digested using 0.2 μg of sequencing-grade
trypsin overnight at 37°C. The obtained mixtures of
peptides were analyzed in an ESI-Ion Trap (Amazon SL,
Bruker Daltonics) mass spectrometer coupled with a
UPLC system (nanoAQUITY, Waters). The effluent
from the nanoLC column, which is an RP C18 pre-
column (nanoACQUITY) connected to a 25-cm-long,
75-μm-i.d. RP C18 column (nanoAQUITY), was directly
introduced into the Ion Trap in positive electrospray
ionization (ESI) mode. Samples were eluted from the
column with a gradient of 4 to 60% ACN in 140 min
(solvent A, 0.1% formic acid; solvent B, 99.9% ACN and
0.1% formic acid) at a flow rate of 0.3 μL/min. Ion trap
charge control (ICC) was used to control ion accumula-
tion in the trap. For precursor ion isolation, a 3-Da win-
dow was set up, and the precursor fragmentation
amplitude was set to 1.0. Acquisitions were run under the
control of Trap Control 7.1 software (Bruker Daltonics).
All SRM data were processed using Data Analysis 4.0 soft-
ware (Bruker Daltonics). The relative quantification values
of each target peptide were determined by calculating the
average ratios of peak areas corresponding to the analyzed
peptides. All data were manually inspected to ensure cor-
rect peak detection and accurate integration.
Statistical analysis
Clinical data: for multiple comparisons of the normally
distributed variables the one-way analysis of variance
(ANOVA) and the Kruskal - Wallis test have been per-
formed. For categorical comparisons chi square test was
performed. P values < 0.05 were considered statistically
significant.
Proteomic data: in 2DE experiments, relative abun-
dance (%vol) of all matched differential spots obtained
for all individual samples in all technical repetitions were
analyzed. Proteins with fold change at least 1.6 were sta-
tistically analyzed. For SRM and LMWP analysis, peak
areas corresponding to the analyzed peptides in all runs
were analyzed. All obtained data were subjected to a
Shapiro-Wilk normality test to check the normal distribu-
tion of the analyzed population. Mann–Whitney U test was
performed to compare protein accumulation between two
particular groups. For multiple comparisons the one-way
analysis of variance (ANOVA) with a Bonferroni correction
for multiple testing was performed. P values < 0.001 and
< 0.01 were considered as statistically significant for 2DE
and SRM/LMWPs data, respectively. For obtained results
regression and correlation analysis were also performed. All
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Bioinformatics analysis
A protein-protein interaction analysis of the identified
proteins was performed using STRING (Search Tool for
the Retrieval of Interacting Genes) v. 8.3 (http://string.
embl.de/) [13] with the following analysis parameters:
species—Homo sapiens, confidence level—0.4 and active
prediction methods—all. STRING is a freely available
database that relies on known and predicted protein in-
teractions and that quantitatively integrates interaction
data from high-throughput experiments, genomic con-
text, co-expression and other literature.
To classify proteins by gene ontology (GO) molecular
function, biological processes and pathway terms both Pan-
ther (www.pantherdb.org) [14,15] and the ProteinScape
software (Bruker Daltonics) were used. The complete data-
set containing all protein identifiers as well as only differ-
ential proteins (>1.6-fold change and p value < 0.001 for
2DE; >2-fold change and p value < 0.01 for LMWP) were
uploaded into the applications. The gene symbols of the
differentially expressed proteins and accumulation levels
were entered in Panther to run the enrichment test to
evaluate likelihood of the numerical values of genes associ-
ated with a particular ontology term. P-values were calcu-
lated using the Mann–Whitney test with Bonferroni
correction for multiple testing with p < 0.05 indicatingFigure 1 A representative example of the 2DE analysis of the LAP (A)
the MARS Hu7 system and resolved by 2DE. IEF was performed at pH 4–7.
(see Additional file 2: Table S1 and S2).statistical significance. The p-value for a given function was
calculated by considering the number of differentially
expressed proteins that participate in given function and
the total number of molecules that are known to be associ-
ated with that function in Panther. The p-value becomes
more significant where a greater number of differentially
expressed proteins are involved.
Results
To increase our knowledge of the mechanisms under-
lying the development of CKDA, we identified the pro-
teins that are differentially accumulated in the plasma of
patients with different stages of CKD, patients with CVD
(and normal renal function) and HVs. The comparative
proteomic analyses were performed between HVs and
each of the groups of CKD patients, between CKD and
CVD patients and between neighboring groups of CKD
patients. In our studies, we focus on three different frac-
tions of plasma proteins: HAPs, LAPs and LMWPs.
Qualitative analysis of immunoaffinity depleted plasma
proteins
In this research depletion of seven highly abundant plasma
proteins using affinity chromatography was performed and
different fractions of proteins: HAPs, LAPs and LMWPs
were obtained. A proteomic map obtained for the LAP
fraction contained, on average, 405 ± 72 spots in all experi-
mental groups (Figure 1A). Among them, 94 uniqueand HAP (B) fractions. Plasma protein samples were depleted using
The proteins identified by mass spectrometry are indexed by number
Luczak et al. Journal of Translational Medicine  (2015) 13:20 Page 7 of 18proteins were identified (Figure 1A, Additional file 2: Table
S1). However, some amounts of the seven depleted pro-
teins, especially albumin, were still detected (Figure 1A).
The 2DE analysis of the HAP fractions resulted in domin-
ant albumin spots and six smaller spots corresponding to
the other proteins removed from blood plasma with the
MARS system. In addition, tens additional protein spots
were visible on the 2DE gels (Figure 1B). These spots were
identified as a 15 unique proteins and are listed in the
HAP fraction table (see Additional file 2: Table S2). The re-
producibility of 2DE gels after MARS depletion was also
assessed by scatter plotting and correlation coefficient de-
termination based on %vol parameter. 77% of gels obtained
for HAPs and LAPs had sufficient reproducibility and were
approved for Image Master analysis (correlation coefficient
above 0.7).2DE analysis of HAPs after immunoaffinity depletion
The HAP fraction contained seven targeted proteins and
15 non-targeted proteins (Figure 1B; Additional file 2:
Table S2). Comparative proteomic analyses of the HAP
fraction allowed for the identification of 3 proteins with
differential accumulation levels: HP, FGG and α-1 m I
(Table 2A, Table 3). The relative abundances of HP and
FGG were increased in the plasma of patients with CKD
and CVD compared with the HV group. The highest
concentrations of both proteins were detected in CKD3-
4 patients (fold changes of 3.7 and 3.95, respectively; p
value < 0.0001), then in patients with CKD1-2 (fold
changes of 3.5 and 3.6; p value < 0.0001) and in patients
with CKD5 (fold change 2.2 and 2.8; p value < 0.0001)
compared with HV. The relative abundances of HP and
FGG in CVD plasma samples were 1.92 and 1.97 times
higher (p value < 0.0001), respectively, compared with
HV samples (Table 2A).
The third differentially expressed protein was α-1 m I,
fragment of preprotein AMBP. The relative abundance
of α-1 m was increased in the plasma of CKD and CVD
patients when compared with HVs. The highest concen-
tration of α-1 m was detected in CKD5 patients (fold
change 2.6; p value < 0.0001), then in CKD3-4 patients
(fold change 2.4; p value < 0.0001). The relative abun-
dance of this protein in CVD plasma samples was 1.98
(p value < 0.001) times higher compared with HV sam-
ples (Table 2A).2DE analysis of LAPs after immunoaffinity depletion
Analysis of the LAP fractions revealed nine differen-
tially expressed proteins: inter-alpha trypsin inhibitor
H4 (ITIH4), transthyretin (TTR), apolipoprotein A1
(APOA1), apolipoprotein B100 (APOB), alpha-2-mac-
roglobulin (A2M), apolipoprotein A-IV (APOA4), the
second isoform of α-1 m protein (α-1 m II), kininogen(KIN) and complement factor C4B (CFB) (Table 2B,
Table 3; Figure 2; Additional file 3).
Comparison between HVs and CKD patients as well as
inside of CKD groups
The relative abundance of TTR was increased in the
plasma of CKD5 patients (fold change 1.79; p value
< 0.0001) compared with HVs (Table 2B, Figure 2A).
APOB was up-regulated in all CKD patients compared
with HVs with p value < 0.0001 (Table 2B, Figure 2B). The
highest level of APOB was detected in CKD3-4 patients
(fold change 3.29). The accumulation of this protein was
2.85 times higher in CKD5 and 1.86 times higher in
CKD1-2 patients compared with HVs. Furthermore, the
relative abundance of this protein was 1.76 times higher in
CKD3-4 compared with CKD1-2 patients.
The relative amount of A2M was increased in the
plasma of CKD3-4 and CKD5 patients, compared with
HVs (Table 2B, Figure 2C). Accumulation of this protein
was 1.72 times higher in the plasma of CKD3-4 patients
and 1.69 times higher in the plasma of CKD5 patients
compared with HVs. Significant differences in accumula-
tion were also obtained for comparisons between CKD1-
2 and CKD5 patients (fold change 1.63) as well as
between CKD1-2 and CKD3-4 patients (fold change
1.65). All these results for A2M were obtained with
p value < 0.0001.
An increase in CFB accumulation was observed
only between CKD3-4 patients and HVs (fold change 1;
p value < 0.0001) (Table 2B, Figure 2D).
The relative abundances of APOA4 and α-1 m II were
increased in the plasma of CKD patients compared with
HVs (Table 2B, Figure 2EF). The accumulations of these
proteins were 1.72 (p value < 0.001) and 1.69 (p value <
0.0001) times higher in CKD1-2 patients for α-1 m II
and APOA4, respectively, compared with HVs. The
highest concentrations of both proteins were detected in
CKD5 patients (fold changes of 4.07 and 2.3, respectively),
and then in CKD3-4 patients (fold changes of 3.17 and
2.18, respectively). Correlation analysis of abundance of
this protein in HV and all CKD patients showed correl-
ation coefficient 0.904 (p < 0.001). Therefore we conclude
that this increase was proportional to the level of CKD
progression (Figure 2F). The relative accumulation of
α-1 m II was 2.36 and 1.93 times lower in CKD1-2 com-
pared with CKD5 and CKD3-4, respectively.
Comparison between HVs and CVD patients
The accumulation levels of APOB and ITIH4 were up-
regulated in CVD patients compared with HVs (fold
changes of 2.08 and 1.6, respectively; p value < 0.0001))
(Table 2B, Figure 2BG).
Compared with HVs, the relative abundances of APOA4
and APOA1 were decreased in the plasma of CVD patients
Table 2 Comparison between abundance of proteins
differentially expressed between HV and CKD/CVD
groups
A Fold change-HAP
Protein CKD1-2 CKD3-4 CKD5 CVD
alpha-1 m I 1.25 2.41** 2.63** 1.98*
HP sum 3.5** 3.7** 2.2** 1.92**
FGG sum 3.6** 3.95** 2.81** 1.97**
B Fold change-LAP
Protein CKD1-2 CKD3-4 CKD5 CVD
alpha-1 m II 1.71** 3.15** 4.05** 1.50
APOA4 1.69** 2.18** 2.3** −1.79**
APOA1 −1.31** −1.36** −1.19* - 1.81**
APOB 1.86** 3.29** 2.85** 2.08**
ITIH4 1.16** 1.25** 1.28** 1.6**
TTR 1.17 1.23 1.79** 1.17
A2M 1.03 1.72** 1.69** −1.05
CFB 1.43** 1.48** 1.41** 1.03
C Fold change- SRM
Protein CKD1-2 CKD3-4 CKD5 CVD
alpha-1 m 2.63** 6.93** 11.82** 3.17**
APOA4 1.52** 2.39** 1.71** −2.25**
HP 5.6** 17.45** 8.19** 3.80**
FGG 6.87** 7.80** 7.81** 2.97**
APOA1 −1.89** −2.39** −1.99** - 2.61**
APOB 2.61** 4.21** 3.23** 2.81**
ITIH4 1.52** 1.55** 1.51** 1.97**
TTR 2.0** 1.89** 2.90** 1.80**
A2M 1.52 1.92** 2.09** 1.57
CFB 1.78** 1.87** 1.54** 1.51**
Table presented fold changes obtained for differentially expressed proteins in
the HAP fraction (A), LAP fraction (B) and in SRM analysis (C). Fold changes
were calculated against the HV group. * - p value < 0.001, ** - p value < 0.0001.
For the actual relative abundances and standard deviations see Table 3.
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0.0001) (Table 2B, Figure 2EH).
Comparison between CKD and CVD patients
Finally, we compared the plasma protein levels in CVD
and CKD patients. The CKD5 and CVD groups differed
in the accumulation of four LAPs with p value < 0.0001.
The relative accumulations of A2M, APOA4, α-1 m II
and APOA1 were always up-regulated in CKD5 patients
compared with CVD patients (fold changes 1.77, 4.14,
2.68 and 1.79, respectively) (Table 2B, Figure 2CEFH).
A comparison of the CVD and CKD3-4 plasma prote-
omic profiles revealed significant differences (p value <
0.0001) of A2M, APOA4 and α-1 m II accumulation.
The relative abundances of these proteins were up-
regulated in CKD3-4 compared with CVD patients, (foldchanges, 1.81, 3.93 and 2.09 for A2M, APOA4 and α-
1 m II, respectively) (Table 2B, Figure 2CEF).
CKD1-2 and CVD groups differed only in the accumula-
tion of APOA4 and APOA1. Relative abundance of these
proteins were 3.04 and 1.62 times higher in CKD1-2 pa-
tients compared with CVD (p value < 0.0001) (Table 2B,
Figure 2EH; Table 2; Additional file 3).
Analysis of LMWPs
To obtain the fraction of LMWPs, individual plasma
samples depleted with MARS columns were centrifuged
using Agilent ultra-filters with a 5-kDa cut-off. The ob-
tained fractions were analyzed without electrophoretic
separation and without trypsin digestion in MS mode in
the m/z range of 2,000-12,000 Da to find differentially
expressed proteins/peptides. The obtained spectra were
analyzed with ClinProTools 2.2. Thirty six differentially
expressed molecules were revealed, with a threshold
greater than 2 and p values below 0.01. PCA showed
that these molecules differentiated among the HV group
and CKD5 and CKD1-2/CVD patients. For these last
groups, a high level of similarity was revealed in this
analysis (Figure 3).
Differentially expressed LMWPs were identified in
LIFT MS/MS experiments. Four components were success-
fully identified: transmembrane and coiled-coil domain-
containing protein (C6orf129), putative uncharacterized
protein and two fragments for complement factor 4
(C4A13). For putative uncharacterized protein, a Blast ana-
lysis was performed to find any functional domains. Unfor-
tunately, this analysis revealed a lack of similarity to any
known proteins. Abundance of C4A13 was up-regulated in
all CKD/CVD patients compared to HV (fold changes 6.08,
6.03 and 9.03 for CKD1-2, CVD and CKD5, respectively)
(Table 3). A list of the peptides/proteins of the LMWP frac-
tion is provided in Additional file 2: Table S3.
Validation of altered proteins by SRM analysis
To confirmation of up- or down-regulation of proteins
identified in 2DE/MS analysis, SRM experiments were
performed. We first optimized the SRM method using
nanoLC-ESI-IT MSn. This technique was then used to
monitor the amounts of identified proteins in samples
from each analyzed group. Using the SRM approach, we
successfully validated the differential accumulation of
ten proteins from the HAP and LAP fractions: α-1 m,
APOA4, A2M, APOA1, CFB, ITIH4, TTR, FGG, HP and
APOB and one protein identified in LMWP fraction
(C4A13). For these proteins, we were able to obtain spe-
cific and “clean” transitions. SRM analyses confirmed
the results obtained using 2DE for all proteins except
one - KIN. Therefore, this protein was excluded from
the list of differentially expressed proteins and from sub-
sequent analysis. The 10 differentially expressed proteins
Table 3 Short characteristic of the proteins differentially expressed in HV, CKD and CVD groups
Protein Accession P value
(ANOVA)
Molecular function (GO) Biological process (GO) Relative abund e ± SD
HV C 1-2 CKD 3-4 CKD 5 CVD
α-1-
microglobulin I
AMBP_Human < 0.0001 peptidase activity; protein
binding; serine-type endopepti-
daseinhibitor activity
immune system process; proteolysis;
regulation of catalytic activity; metabolic
process
0.104 ± 0.03 0. ± 0.03 0.249 ± 0.08 0.273 ± 0.06 0.206 ± 0.04
α-1-
microglobulin II
AMBP_ Human < 0.0001 0.091 ± 0.02 0. ± 0.04 0.289 ± 0.07 0.371 ± 0.05 0.138 ± 0.03
Apolipoprotein
A-IV
APOA4_ Human < 0.0001 enzyme regulatoractivity;
protein binding; lipid binding
transporter activity
cell communication; regulation of catalytic
activity; response to stimulus; transport;
blood circulation; lipid metabolic process
1.033 ± 0.16 1. ± 0.17 2.260 ± 0.24 2.378 ± 0.25 0.574 ± 0.15
Apolipoprotein
A-I
APOA1_ Human < 0.0001 enzyme regulator activity;
protein binding; lipid binding;
transporter activity
cell communication; regulation of catalytic
activity; response to stimulus; transport;
blood circulation; lipid metabolic process
4.25 ± 0.17 3. ± 0.13 3.116 ± 0.67 3.581 ± 0.68 2.00 ± 0.17
Apolipoprotein
B-100
APOB_ Human < 0.0001 protein binding; lipid binding;
transporter activity
cell communication; regulation of catalytic
activity; response to stimulus; transport;
blood circulation; lipid metabolic process
0.579 ± 0.33 1. ± 0.10 1.907 ± 0.18 1.649 ± 0.19 1.207 ± 0.19
α-2-
macroglobulin
A2MG_ Human < 0.0001 peptidase activity; cytokine
activity; serine-type endopep-
tidase inhibitor activity
complement activation; proteolysis; cell
communication; response to stimulus;
regulation of catalytic activity; lipid
metabolic process; platelet activation
1.163 ± 0.10 1. ± 0.13 1.995 ± 0.13 1.961 ± 0.14 1.104 ± 0.16
Transthyretin TTHY_ Human < 0.001 protein binding;
transmembrane transporter
activity
cell communication; transport; metabolic
process; regulation of catalytic activity;
response to stimulus




ITIH4_ Human < 0.0001 peptidase activity; protein
binding; serine-type endopep-
tidase 7inhibitor activity
proteolysis; immune system process;
regulation of catalytic activity; response to
stimulus
1.492 ± 0.18 1. ± 0.07 1.861 ± 0.08 1.913 ± 0.06 2.396 ± 0.11
Complement
factor B
CFAB_ Human < 0.0001 peptidase activity; cytokine
activity; serine-type endopep-
tidase inhibitor activity
cell communication; blood coagulation;
immune system process; metabolic process;
regulation of catalytic activity; response to
stimulus; transport; proteolysis
0.363 ± 0.07 0. ± 0.06 0.593 ± 0.06 0.510 ± 0.05 0.371 ± 0.06





gamete generation; immune system
process; proteolysis; cell communication;
blood circulation; response to stress; blood
coagulation; metabolic process
1.073 ± 0.57 3. ± 0.59 3.970 ± 0.25 2.361 ± 0.65 2.060 ± 0.62
Fibrinogen γ FIBG_ Human < 0.0001 receptor binding cell communication; cell-matrix adhesion;
cell-cell adhesion; blood coagulation;
1.677 ± 0.63 6. ± 0.79 6.626 ± 1.13 4.714 ± 0.79 3.304 ± 0.72
Complement
factor C4A
CO4A_Human < 0.0001 peptidase activity; cytokine
activity; serine-type endopep-
tidase inhibitor activity
immune system process; proteolysis; cell
communication; response to stimulus;
regulation of catalytic activity


































YK026_HUMAN < 0.0001 No hit No hit 0.91 ± 0.09 1.46 ± 0.60 3.38 ± 0.36 1.48 ± 0.13
The spots corresponding to these proteins showed at least a 1.6-fold increase or reduction of relative abundance. Molecular functions and biological processes for all proteins were defined using GO annotations.











Figure 2 Relative abundance of proteins differentially expressed in HV, CKD and CVD groups. Relative accumulation (%vol) of TTR (A),
ITIH4 (B), APOB (C), A2M (D), CFB (E), APOA4 (F), α-1 m II (G) and APOA1 (H) in HV, CKD1-2, CKD3-4 and CVD plasma samples. * - p value < 0.001,
** - p value < 0.0001. P values refer only to the comparison with HV group. For the other p values see Additional file 3.
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mulation trends as observed in 2DE analysis (Table 2,
Figure 2). For some proteins insignificant in the 2DE
analysis, the SRM data showed statistical significance.
For TTR, the SRM analysis showed more meaningful
differences in the relative abundance compared with the
2DE analysis (i.e. for comparison between the CKD3-4
and HV groups, fold change for SRM was 1.89, instead
of 1.23 for 2DE analysis). Differences in accumulation
between HVs and CKD1-2 or CKD3-4 patients were
more visible for CFB as well (respective fold changes of
1.78 and 1.87 instead of 1.43 and 1.48 in the 2DE ana-
lysis) (Table 2B). Although the magnitude of the relative
ratios of the validated proteins differed between tech-
niques used, the direction of change in expression for
the validated protein spots was consistent between 2DE
and SRM analyses. It should be noted that differences in
the accumulation of particular proteins were always
more pronounced in SRM analysis compared with 2DE
analysis. Examples of the SRM analysis for α-1 m and
APOA4 peptides are shown in Figures 4 and 5.
Identification of functional networks associated with CKD
and CVD
To gain knowledge about the molecular mechanisms of
atherosclerosis that distinguish between patients withCKD and CVD we mapped protein identifiers from the
source databases to their corresponding identifiers in the
STRING database. As a result a network using putative
protein-protein association data was created. In order to
perceive the distribution of the differentially expressed
proteins within important molecular functions and bio-
logical processes, clustering of differential proteins based
on the Gene Ontology (GO) Consortium [14] annota-
tions was created. STRING reveals three functional
nodes: blood coagulation proteins (FGG, A2M); acute
phase proteins and proteins involved either directly or
indirectly in immune reactions (α-1 m, A2M, ITIH4,
TTR, HP, C4A13 and CFB) as well as proteins that par-
ticipate in the binding and catabolism of lipoprotein par-
ticles (APOB, APOA4, APOA1, and A2M); (Figure 6A).
The most of putative connection indicate that main func-
tions of differential proteins are binding (blue lines) and
catalysis (black lines). These data are consistent with re-
sults obtained from Gene Ontology analysis. Above 85%
of identified differential proteins are involved in binding
function mostly in protein and lipid binding (Figure 6B).
Also functions related with enzyme activity are dominated.
GO analysis of biological processes shows that majority
identified differential proteins are involved in metabolic
processes, mainly lipid metabolic processes and cell com-
munication (Figure 6C). Moreover, GO analysis of all
Figure 3 PCA of the LMWP fraction. PCA of the LMWP fraction
obtained from the plasma of HV (yellow), CVD (blue) CKD1-2 (green) and
CKD5 (red) patients. Calculations were performed with ClinProTools 2.2.
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teins) reveals 18 proteins involved in cell communication.
Half of these proteins were up- or down-regulated in
plasma CKD and CVD patients. As in the case of STRING
analysis blood coagulation proteins and proteins related
with immune responses (response to stimulus and im-
mune reactions) were also relative over-represented to
other proteins.Discussion
We performed proteomic analyses of blood plasma to
increase our knowledge of the mechanisms involved in
the development of atherosclerosis in CKD and to evalu-
ate the differences between CKD- and CVD-associated
atherosclerosis. We focused on three different fractions
of plasma proteins: HAPs, LAPs and LMWPs. As a re-
sult, 13 differentially expressed proteins and 36 differen-
tially expressed small molecules with masses ranging
from 2 to 5 kDa were identified. It is known fact that
2DE has some limitations, especially low resolution and
gel-to-gel and run-to-run variability in the expression of
the same protein set. For that reason only proteins with
restrictive p value below 0.001 and validated using SRManalysis were accepted as a differentially accumulated
proteins.
Among the HAP fraction, three proteins, α-1 m I,
FGG and HP, revealed differential expression in the ana-
lyzed groups. In the case of α-1 m, two isoforms were
identified and both displayed differential accumulations,
in the HAP (α-1 m I) and LAP (α-1 m II) fractions.
One of the main drawbacks of removing abundant
proteins from plasma using affinity column is the simul-
taneous removal of non-targeted proteins [16]. The pres-
ence of α-1 m I in the HAP fraction may be related to
its non-specific binding to proteins in the HAP fraction.
A broad literature search revealed that the non-targeted
removal of proteins could be accomplished using affinity
systems. Approximately 50% of α-1 m in human plasma
forms a complex with IgA, 7% is linked to albumins and
1% is bound to prothrombin [17] or coagulation factors
(reviewed in [18]). Our study suggests that at least one
of the α-1 m isoforms is associated with carrier proteins
and that this isoform differentiates between the analyzed
groups of patients. Furthermore, in the HAP fraction,
we identified 15 other non-targeted proteins (Additional
file 2: Table S2). Gundry et al. described the ‘albumi-
nome,’ which consists of 35 proteins from plasma that
co-elute with albumin via the anti-HSA depletion system
[19]. From our list of identified non-targeted proteins,
we found 9 proteins that match the Gundry ‘albumi-
nome’ list (Additional file 2: Table S2). Others also
showed the removal of non-targeted proteins using
MARS-Hu6, MARS-Hu14 and Proteoprep20 depletion
systems and some of these proteins matched our data
[20-22]. Albumin seems to be a main candidate for the
carrier protein. However, other proteins i.e. histidine-
rich glycoproteins [23], CD5 antigen-like protein [24],
clusterin [25] and HP [26] may also have a significant role
in non-targeted binding. Altogether, the data obtained
here confirm the fact that analyses of both fractions, LAP
and HAP, after affinity depletion are necessary in the
search for differential proteins and potential biomarkers.
Among the LAP fraction, eight proteins were identi-
fied and validated as differentially expressed between the
analyzed groups of patients: the second isoform of α-
1 m (α-1 m II), TTR, ITIH4, APOA1, APOA4, A2M,
APOB and CFB (Table 2B, Table 3; Figure 2). Analysis of
the obtained spectra for LMWPs revealed the presence
of 36 differentially expressed proteins/peptides. Unfortu-
nately, only four compounds were successfully identified.
Bioinformatics tools were used to analyze the functional
interactions of the identified differentially expressed pro-
teins and their functional partners. These proteins were
integrated into biological association networks based on
the STRING database, which relies on known and pre-
dicted protein interactions [13]. All the identified pro-
teins were analyzed also for their involvement in known
Figure 5 An example of the SRM analysis of APOA4. A. The extracted ion chromatograms of the SRM transitions of the SLAELGGHLDQQVEEFR
peptide of APOA4 in HV, CKD1-2, CKD3-4 and CVD plasma. B. The MS/MS spectrum of the transition 643.4 - > 580.4 m/z (parent mass - > fragment mass).
Figure 4 An example of the SRM analysis of α-1 m. A. The extracted ion chromatograms of SRM transitions of the ETLLQDFR peptide of
α-1 m in HV, CKD1-2, CKD3-4, CKD5 and CVD plasma. B. The MS/MS spectrum of the transition 511 - > 565.5 m/z (parent mass - > fragment mass).
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Figure 6 Bioinformatic analysis of the differentially expressed proteins. A. Predicted interaction network of the differentially expressed
proteins and their putative functional partners. The proteins were analyzed using the STRING database 9.0. Nodes represent proteins. The predicted
functional interaction networks are shown in the action view where the different associations are represented by differently colored lines. Each interaction
between nodes is supported by the literature. APOE - apolipoprotein E; HP - haptoglobin; TTR – transthyretin; C4A13 -complement C4A; AMBP - α-1 m;
ITIH4 - inter alpha-trypsin inhibitor H4; FGG – Fb gamma; APOA4 – apolipoprotein A4; C6orf127 - transmembrane and coiled-coil domain-containing
protein, FGA - fibrinogen alpha chain, FGB - fibrinogen beta chain, LCAT- lecithin-cholesterol acyltransferase, LIPC - lipase, hepatic, ABCA1 - ATP-binding
cassette, sub-family A (ABC1), F2 - coagulation factor II (thrombin), LDLR - low density lipoprotein receptor, APOA2 - apolipoprotein A-II, RBP4 –
retinol-binding protein 4, APOC3 - apolipoprotein C-III. B, C. Classification of the identified differentially expressed proteins in molecular function (B) and
biological processes (C) on the basis of gene ontology (GO) annotations. * indicate processes with p value below 0.05.
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ing to GO annotation [14,15]. STRING analyses revealed
that the proteins identified in our study are related to at
least three different processes: the blood coagulation cas-
cade, the transport, binding and metabolism of lipopro-
teins, and inflammatory processes (Figure 6A). Gene
Ontology analysis also strongly indicated on protein/lipidbinding and transport. Almost all differential proteins
were also involved in immune reactions or responses to
stimulus as well as in cell communication (Figure 6B,C).
The most puzzling result from our study is high simi-
larity between abundance of some proteins between
CKD1-2 and CVD patients. Plasma from both of these
groups of patients showed similar accumulations of
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domain-containing protein 167 and putative uncharac-
terized protein LOC100129027 (Table 3; Figure 2ABCF).
Also an analysis of the obtained spectra for LMWP and
performed PCA revealed high similarity between CKD1-
2 and CVD patients (Figure 3). Patients from the CVD
and CKD1-2 groups differ considerably in the history of
the cardiac events and progress of atherosclerosis. The
CVD patients selected for this study had a rich history
of myocardial infarction and/or coronary angioplasty. In
contrast, CKD1-2 patients showed the first symptoms of
hypertension or ischemic heart disease. On the other
hand CKD5 and CVD groups have similarly severe ath-
erosclerosis symptoms and a high percentage of cardio-
vascular events (Table 1). However, the latter groups of
patients differed in the accumulation of four identified
differentially expressed proteins. These proteins (A2M,
APOA4, α-1 II and APOA1) were up-regulated in CKD5
patients compared with CVD patients (Figure 2CEFH).
Additionally, PCA of LMWPs showed that these groups
are completely distinct from each other (Figure 3). This
definitely indicates that similar proteomic profile be-
tween CKD1-2 and CVD patients are not associated
with severity of atherosclerosis. This finding also sup-
ports completely different proteomic profile between
CVD and CKD5 patients. It may suggest that mechan-
ism of CVD acceleration is different in initial and ad-
vanced stages of CKD. However, these relationships
need to be investigated further.
It is known that both traditional as well as novel car-
diovascular risk factors support atherosclerosis progres-
sion in CKD. Our results prove undoubtedly that
compared to initial CKD, patients with more advanced
kidney failure have increased inflammation. This finding
is confirmed not only by the increased levels of serum
CRP (Table 1) but also by the differential accumulation
of proteins that are involved in immune reactions and
act as acute phase proteins, including α-1 m, ITIH4,
TTR, HP, FGG, A2M, C4A13 and CFB, which had the
highest abundances in the plasma of CKD3-4 and CKD5
patients (Table 3; Figure 2). Our results show that com-
pared with CVD patients, the plasma of CKD3-4 and
CKD5 patients demonstrated an increased acceleration
of inflammatory processes and were less affected by ab-
normalities in cholesterol transport or metabolism.
ITIH4 is a known positive acute-phase response plasma
protein and is synthesized mainly in the liver [27]. Pro-
teins CFB and C4A13 are components of the comple-
ment system and are also related to inflammatory
processes [28]. Little is known about changes in the accu-
mulation of complement factors in patients with CKD and
CVD. However, atherosclerosis is a chronic inflammatory
disorder that is influenced by activation of the comple-
ment system, and complement activation is extensivelystimulated in atherosclerotic lesions [29-31]. Despite this,
level of both proteins was higher in plasma patients with
advanced CKD compared to CVD patients.
Second group of the differential proteins identified in
our study are molecules involved in the transport, bind-
ing and metabolism of lipoproteins. As demonstrated by
our data, changes are found in the profile of proteins in-
cluding APOA4, APOA1 and APOB. Undoubtedly, these
proteins are altered in CVD compared to HV. Also pa-
tients with impaired renal function exhibit significant
abnormalities in profile of proteins related with lipopro-
tein metabolism. However character of these changes is
different in CKD and CVD group of patients.
APOB and APOA1 are critical for lipoprotein forma-
tion, stability and clearance [32]. APOB, which is present
in VLDL, IDL, and LDL, reflects the total number of
atherogenic particles and is required for their formation
[33]. High levels of APOB can enhance the progression
of the formation of atherosclerotic plaques [34]. In turn,
as the main protein component of anti-atherogenic HDL
particles, APOA1 has anti-atherogenic potential due to
its central role in the reverse cholesterol transport sys-
tem and in the transfer of excess cholesterol from per-
ipheral cells back to the liver [35,36]. Our results
showed that all CKD patients have an increased level of
APOB compared with HVs (SRM fold change between
2.61 and 4.21). Once again, we observe a conspicuous
similarity between CKD1-2 and CVD patients (%vol
1.207 ± 0.19 and 1.080 ± 0.10 for CVD and CKD1-2, re-
spectively) (Table 3). In contrast, a decrease in the accu-
mulation of APOA1 was observed in all groups of CKD
patients compared with HVs, but huge differences were
visible when comparing CKD and CVD patients
(Figure 2G). This evidence highlights the limitations of
traditional lipid profile measurements, especially LDL
cholesterol, as markers of cardiovascular risk in persons
with CKD.
In addition to APOA1, APOA4, which was also re-
vealed in our study as an important differentiating pro-
tein, is involved in reverse cholesterol transport and thus
plays an anti-atherogenic and antioxidative role [37]. De-
creased levels of APOA4 in the plasma of patients with
CVD were observed. In contrast, in patients with CKD,
APOA4 increased proportionally with impaired renal
function. The relationship between the concentrations of
this protein and progression of CKD suggests that high
levels of APOA4 may have an anti-atherogenic effect,
only in the case of classical CVD (Figure 2E). In CKD
patients association between high level of APOA4 and
an anti-atherogenic result is not efficient. Also, the
APOA1 abundance suggests that the relationship be-
tween anti-atherogenic factors and the risk of cardiovas-
cular events is not functional in patients with CKD, in
contrast to classical CVD. Most likely, this risk in
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traditional risk factors, such as inflammation. The simi-
larity between APOB abundance in CKD1-2 and CVD
patients also suggests that this phenomenon is particu-
larly more pronounced in the more advanced stages of
CKD. Therefore, there is no doubt that progressive CKD
is accompanied by the development of specific alter-
ations of lipoprotein metabolism but in a manner dis-
tinct from classical CVD.
The latter observation may be explained by the discov-
eries from large randomized controlled trials concerning
the reduction in cardiovascular risk caused by statins in
CKD patients [38-40]. Lipid-lowering therapy with sta-
tins was not effective in reducing the risk of cardiovas-
cular morbidity and mortality in patients with very
advanced stages of CKD, despite the significant reduc-
tion in LDL concentrations [40-44].
This treatment was only effective in patients with mild
and moderate stages of CKD [38,39,45]. In another large
trial, the reduction of the risk of cardiovascular events
was higher (20%) in non-dialyzed subjects when com-
pared with hemodialyzed subjects (9%) [46]. And finally,
according to the latest data statins are do not recom-
mended for the primary prevention of CVD in dialysis
patients [47]. This may suggest that risk of cardiac
events in advanced CKD is not directly related with ab-
normalities in lipids metabolism. CKD5 patients (also in
our study) have decreased serum cholesterol concentra-
tions compared with patients with mild and moderate
stages of CKD. Moreover, CKD1-2 patients exhibit in-
creased total cholesterol and LDL cholesterol when
compared with CKD3-4 patients despite the fact that
greater percentage of CKD1-2 patients received statins
(Table 1). Negative association between cholesterol levels
and mortalities in dialyzed patients were presented few
times [48-50]. Thus, this reverse epidemiology may ex-
plain the worse effects of lipid-lowering therapies in pa-
tients with advanced stages of CKD.
Conclusions
Taken together, the findings of these analyses support the
concept that different mechanisms are involved in the for-
mation of CVD- and CKD-related atherosclerosis. APOB,
APOA1 and APOA4 abundance suggests that the rela-
tionship between atherogenic and anti-atherogenic factors
and the risk of cardiovascular events is not functional in
patients with CKD, in contrast to classical CVD. This evi-
dence highlights the limitations of traditional lipid profile
measurements, as indicators of risk of cardiac events in
CKD patients. Moreover, our results also suggest that
mechanism of CVD acceleration may be different in initial
and advanced stages of CKD. In more advanced stages of
CKD, non-traditional risk factor, inflammation, is highly
pronounced. The most puzzling result seems to be similarproteomic profiles between CVD and CKD1-2 patients,
groups which are considerably different in the severity of
the atherosclerosis. These relationships are unclear and
further research should focus on precise resolving this
issue.
Additional files
Additional file 1: Details of SRM analysis. Protein-derived peptides,
transitions and retention times selected from LC-MS/MS spectra for SRM
verification of the differential abundance levels of TTR, ITIH4, APOB, A2M,
APOA1, CFB, α-1 m, FGG, HP and APOA4.
Additional file 2: Proteins identified in the plasma of HVs, CKD and
CVD patients. Table S1. A. Proteins identified in the LAP fraction of the
plasma of CKD and CVD patients after MARS Hu7 depletion. Spots
corresponding to the particular numbers are shown in Figure 1A. RMS -
root mean square value indicating on deviation from predicted mass. B,
C. GO distribution of CKD/CVD plasma proteome in term of biological
process (A) and molecular function (B). Table S2. Proteins identified in
the HAP fraction of the plasma of CKD and CVD patients after MARS Hu7
depletion. Spots corresponding to the particular numbers are shown in
Figure 1B. RMS - root mean square value indicating on deviation from
predicted mass. Table S3. Results of analysis of the LMWP fraction. A. An
analysis of the obtained MS spectra performed with ClinProTools 2.2
revealed the presence of 36 differentially expressed molecules with
p values below 0.01. Three components were identified by fragmentation
in MS/MS mode: transmembrane and coiled-coil domain-containing
protein (C6orf129), putative uncharacterized protein and complement
factor 4 (C4A13). Index - number of component; Mass - molecular mass
of components; DAve - difference between the maximal and the minimal
average peak area/intensity of all classes; PTTA - p value of t-test; CKD5, CVD,
HV, CKD1-2 - peak area/intensity of given component. B. MALDI-TOF/TOF
fragmentation spectrum of peptide fragment NGFKSHALQLNNRQIR,
representing the C4A13 protein; the y series ions reflected the amino acid
sequence.
Additional file 3: Statistical analysis of differences in accumulation
of differential proteins in HV, CKD and CVD samples. p values
generated using Bonferroni test (Statistica v. 10.0) for multiple testing
between all analyzed experimental groups after 2DE (A) and SRM (B)
analysis. Differences identified as significant (p > 0.001) are bolded.
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